Le Lézard
Classified in: Health
Subject: LAW

Energy and Commerce Committee Reviews Newly Uncovered Evidence on Citizens Who Received Heart Devices Across the United States From 2006-2008 During Open Heart Surgery


WASHINGTON, Feb. 13, 2020 /PRNewswire/ -- Dr. Rajamannan, Most Sacred Heart of Jesus Cardiology and Valvular Institute Medical Director, continues the effort to inform the patients of the clinical studies using heart valves invented by surgeons across the United States. The Energy and Commerce House Committee has received the new evidence this week regarding statements by Northwestern University made in December 2019 to the Illinois Supreme Court stating that the heart device, the Myxo ETlogix was "FDA approved in 2006," during the clinical study published in the Lead Journal of the American Association of Thoracic Surgeons in July 2008.

Presenting evidence to the Energy and Commerce Committee and Senate Finance Committee

The Energy and Commerce Committee held oversight hearings in August 2009 which included Dr. Marcia Crosse from the Government Accountability Office and Dr. William Maisel who at the time of the hearings, was an Associate Professor of Medicine at Harvard Medical School with more than 15 years of clinical experience as a Board?certified cardiologist. Dr. Maisel is currently the Chief Medical Officer and Director of the Office of Device Evaluation at FDA's Center for Devices and Radiological Health. He is responsible for providing leadership in the development, implementation, execution, management and direction of the Center's broad national and international biomedical science programs. Dr. Maisel confirmed to the oversight committee that the device was not approved for use in humans during the study and that the device was placed on recall after the patients received the device without FDA oversight.

Dr. Rajamannan, who has submitted evidence to the Energy and Commerce committee from 2009 to 2020, also presented the FDA Affidavit summarizing the patients' injuries, as published in The Daily Northwestern in May 2019.

The New Evidence Provided to the House Committee on Energy and Commerce include:

The Energy and Commerce Committee health committee which has oversight Jurisdiction includes public health and quarantine; public health insurance (Medicare, Medicaid) and private health insurance; medical malpractice and medical malpractice insurance; the regulation of food, drugs, devices, cosmetics, and tobacco (the Food and Drug Administration); drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.

Dr. Nalini Rajamannan is a heart valve expert in the field of cardiovascular medicine. She earned her undergraduate science pre-professional degree from the University of Notre Dame, her Medical Doctorate from Mayo Medical School and her post-graduate training in Internal Medicine and Cardiology at the Mayo Clinic and Research Fellowship on the NIH training Grant. She also worked at the Mayo Clinic as a staff consultant in Internal Medicine and an Associate Professor of Medicine at Northwestern University and the Lakeside and Westside VA. Currently, she practices consultative valvular medicine and Osteocardiology at Most Sacred Heart of Jesus Cardiology and Valvular Institute, WI.

Press Contact
Oscar Delgado
Press Officer for Most Sacred Heart of Jesus Cardiology and Valvular Institute
Former NBC Bureau Chief Latin America
773-573-6890
[email protected]

Related Files

+Page 5_Testimony_Maisel_Energy_Commerce_2009.pdf

FDAAffidavit_ Investigation MPLS_FDA and Testimony from the Victims_12-19-2018+JMJ.pdf

Related Images

dr-rajamannan-presenting-evidence.jpg
Dr. Rajamannan presenting evidence to Congress in Washington DC
Presenting evidence to the Energy and Commerce Committee and Senate Finance Committee

dr-rajamannan.jpg
Dr. Rajamannan

Related Links

NBC 26 Interviews Patients

Most Sacred Heart of Jesus Cardiology

SOURCE Most Sacred Heart of Jesus Cardiology


These press releases may also interest you

at 02:05
PureTech Health plc ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results...

at 02:05
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024      Strong commercial...

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...

at 00:00
Health Carousel, renowned for its dedication to enhancing the healthcare staffing sector, today unveiled its groundbreaking 'Full Circle of Support' program. This initiative represents a significant investment in the total well-being of its...

17 avr 2024
TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

17 avr 2024
SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM and 1st Credentialing, is providing notice of a recent data security event that may affect the security of information related to certain individuals. SysInformation is...



News published on and distributed by: